·   Log in

Suven’s 5-HT compounds to treat Alzheimer’s, schizophrenia get more patents from New Zealand and India

Tagged with:
Wednesday, April 28, 2010, 18:54 This news item was posted in Patents category and has 0 Comments so far.

Suven Life’s investigative 5-HT compounds with a potential to treat neurodegenerative disorders won patents from New Zealand and India.

The New Zealand Patent Office has issued a Patent: 548743 and the Indian Patent Office has issued a patent: 238017 to their New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

These Patents are valid until 2024 and 2025 respectively, Suven Life Sciences Ltd announced.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, ADHD, Parkinson, Schizophrenia and Huntington’s diseases.

With these new patents, Suven has total of 7 granted New Zealand product patents and 9 granted Indian product patents on NCEs.

Suven Life Sciences has recently been granted patents for three new chemical entities (NCEs) from Australian patent office for the treatment of disorders associated with neurodegenerative diseases.

With these new patents, Suven has total seven granted Australian patents on NCEs.

The company is planning to out-licensed these products at various stages of clinical development like at phase-I or phase-II.

Recently, Suven Life Sciences Ltd was issued a product Patent, 4460446 to one of their new chemical entity (NCE) which is for the treatment of disorders associated with neurodegenerative diseases by the Japanese Patent Office (JPO).

There are several product patent applications from Suven Discovery Research are in the pipeline and Suven secured intellectual property protection for several of their NCEs in all major markets like USA, Canada, Europe, China, Russia, India, Japan, Australia, New Zealand, Brazil and Mexico.

In March, Suven Life Sciences Ltd secured another patent from the European Patent Office (EPO) for lead molecule which has a potential to treat neurodegenerative diseases.

The European Patent Office (EPO) has issued a product Patent No: EP1919896 to one of their New Chemical Entity (NCE) which is for the treatment of disorders associated with neurodegenerative diseases, Suven announced in a press release.

All the eight EPO patents have been validated in the 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, United Kingdom, Italy, Netherlands, Poland, Sweden and Finland etc.

In November 2009, Suven Life Sciences Ltd was granted three new patents by the European Patent Office for its research relating to neurodegenerative diseases.

In October, Suven Life Sciences Ltd secured product patents for SUVN-502 in nine regions. SUVN-502 is Suven Life’s experimental drug for treating cognitive defects associated with Alzheimer’s disease and schizophrenia.

Suven Life Sciences has secured product patents for SUVN-502 in  countries including India, Mexico, South Africa, Singapore, New Zealand, Korea, Eurasia, Australia and Europe. SUVN-502 patent is valid till June 2023 in all these countries.

Suven Life Sciences completed its phase I trials for SUVN-502 in April 2009.

SUVN-502 is a lead compound intended for the symptomatic treatment of Alzheimer’s disease and other disorders of memory and cognition like attention deficient hyperactivity, Parkinson, Schizophrenia. Suven Life is planning to initiate the clinical Phase-II proof of concept studies for SUVN-502 during 2010. Suven Life may launch SUVN-502 in later 2013 or in early 2014.

In September, Suven Life Sciences Ltd secured two new US patents for its class of selective 5-HT compounds for the treatment of disorders associated with neurodegenerative diseases like Alzheimer’s disease, Parkinson and schizophrenia .

Suven secured its first US product patent no. US 7,297,711 in December 2007. The granted claims of the patent include the class of selective Serotonin receptor affinity compounds discovered by Suven.

In January 2008, Suven announced that the company received its second product Patent number US 7,317,035.  According to the invention ‘035 patent disclosure, the compounds are useful in the treatment of neurodegenarative disorders like Alzheimer’s, Parkinson, Schizophrenia and Huntington’s.

Suven has so far filed 29 product patent applications through PCT covering more than 145 countries, out of which 5 product patents are granted in various countries. The new patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II, the release stated.

Recently, Suven Life Sciences announced that the company received first milestone payment from Eli Lilly for drug discovery collaboration in central nervous system (CNS) disorder. Suven achieved with the identification and selection of a 1st Lead compound to be advanced into Lead Optimization Phase of preclinical development.

Suven entered into drug discovery collaboration with Eli Lilly and Company, USA to jointly discover and develop candidates for the treatment of CNS disorders,in 2008. Under the terms of the agreement Lilly will undertake the clinical development of the selected candidate/s and commercialization globally. Lilly will have the full ownership of the candidates developed under this collaboration while Suven receives ongoing research payments and preclinical milestones.

The contract also provides substantial long-term upside for Suven through potential payments for successful milestones achieved during clinical development and royalties on worldwide sales if new drugs are commercialized.

Hyderabad-based Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing therapies through the use of GPCR targets.

Scroll down to comment on this story
You can leave a response, or trackback from your own site.

Leave a Reply